Bausch Health Cos Inc. (NYSE:BHC) Receives $8.33 Consensus PT from Brokerages

Bausch Health Cos Inc. (NYSE:BHC) has been given an average rating of “Reduce” by the five ratings firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and four have assigned a hold rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $8.3333.

Several equities analysts have commented on the company. Wall Street Zen downgraded Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a research report on Sunday, February 15th. Weiss Ratings lowered shares of Bausch Health Cos from a “hold (c)” rating to a “sell (d+)” rating in a research note on Thursday, February 19th. Barclays cut their price target on shares of Bausch Health Cos from $8.00 to $7.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 25th. Truist Financial raised their price target on shares of Bausch Health Cos from $7.00 to $8.00 and gave the stock a “hold” rating in a research note on Wednesday, January 7th. Finally, Raymond James Financial reissued a “market perform” rating on shares of Bausch Health Cos in a research report on Monday, January 26th.

Hedge Funds Weigh In On Bausch Health Cos

Large investors have recently bought and sold shares of the business. Dynamic Technology Lab Private Ltd purchased a new position in Bausch Health Cos in the first quarter valued at about $68,000. Jones Financial Companies Lllp boosted its stake in Bausch Health Cos by 1,548.9% in the first quarter. Jones Financial Companies Lllp now owns 24,965 shares of the company’s stock valued at $162,000 after acquiring an additional 23,451 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in Bausch Health Cos by 97.1% in the first quarter. Goldman Sachs Group Inc. now owns 948,322 shares of the company’s stock worth $6,136,000 after purchasing an additional 467,270 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Bausch Health Cos by 3.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 324,847 shares of the company’s stock worth $2,102,000 after purchasing an additional 9,834 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Bausch Health Cos by 11.2% during the second quarter. Geode Capital Management LLC now owns 840,418 shares of the company’s stock worth $5,597,000 after purchasing an additional 84,892 shares in the last quarter. Institutional investors own 78.65% of the company’s stock.

Bausch Health Cos Stock Up 7.3%

BHC opened at $5.40 on Friday. The company has a market capitalization of $2.01 billion, a PE ratio of 12.85 and a beta of 0.37. The firm has a 50-day simple moving average of $5.65 and a two-hundred day simple moving average of $6.34. The company has a quick ratio of 1.08, a current ratio of 1.47 and a debt-to-equity ratio of 54.68. Bausch Health Cos has a 52 week low of $4.25 and a 52 week high of $8.69.

Bausch Health Cos (NYSE:BHC) last posted its earnings results on Wednesday, February 18th. The company reported $1.08 earnings per share for the quarter, missing analysts’ consensus estimates of $1.21 by ($0.13). The business had revenue of $2.78 billion during the quarter, compared to analysts’ expectations of $2.71 billion. Bausch Health Cos had a net margin of 1.53% and a return on equity of 875.00%. Analysts forecast that Bausch Health Cos will post 4.41 earnings per share for the current fiscal year.

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.